221 related articles for article (PubMed ID: 33363469)
1. Population Pharmacokinetics and Model-Based Dosing Optimization of Teicoplanin in Pediatric Patients.
Zhang T; Sun D; Shu Z; Duan Z; Liu Y; Du Q; Zhang Y; Dong Y; Wang T; Hu S; Cheng H; Dong Y
Front Pharmacol; 2020; 11():594562. PubMed ID: 33363469
[No Abstract] [Full Text] [Related]
2. Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis.
Chen CY; Xie M; Gong J; Yu N; Wei R; Lei LL; Zhao SM; Li RM; Dong X; Zhang XL; Zhou Y; Li SL; Cui YM
Front Pharmacol; 2023; 14():1132367. PubMed ID: 37188268
[No Abstract] [Full Text] [Related]
3. Optimal Teicoplanin Dosage Regimens in Critically Ill Patients: Population Pharmacokinetics and Dosing Simulations Based on Renal Function and Infection Type.
Wang Y; Yao F; Chen S; Ouyang X; Lan J; Wu Z; Wang Y; Chen J; Wang X; Chen C
Drug Des Devel Ther; 2023; 17():2259-2271. PubMed ID: 37546521
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic Model-Based Evaluation of Standard Dosing Regimens for Cefuroxime Used in Coronary Artery Bypass Graft Surgery with Cardiopulmonary Bypass.
Alqahtani SA; Alsultan AS; Alqattan HM; Eldemerdash A; Albacker TB
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29358296
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and dosing optimization of unbound teicoplanin in Chinese adult patients.
Fu WQ; Tian TT; Zhang MX; Song HT; Zhang LL
Front Pharmacol; 2022; 13():1045895. PubMed ID: 36506535
[No Abstract] [Full Text] [Related]
6. Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?
Kontou A; Sarafidis K; Begou O; Gika HG; Tsiligiannis A; Ogungbenro K; Dokoumetzidis A; Agakidou E; Roilides E
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932366
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics and Dose Optimization of Teicoplanin during Venoarterial Extracorporeal Membrane Oxygenation.
Wi J; Noh H; Min KL; Yang S; Jin BH; Hahn J; Bae SK; Kim J; Park MS; Choi D; Chang MJ
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674057
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy.
Byrne CJ; Roberts JA; McWhinney B; Ryder SA; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; D'Arcy DM; McHugh J
Clin Microbiol Infect; 2017 Sep; 23(9):674.e7-674.e13. PubMed ID: 28267636
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics and Dosage Optimization of Teicoplanin in Children With Different Renal Functions.
Gao L; Xu H; Ye Q; Li S; Wang J; Mei Y; Niu C; Kang T; Chen C; Wang Y
Front Pharmacol; 2020; 11():552. PubMed ID: 32431611
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and model-based dosing optimization of teicoplanin in elderly critically ill patients with pneumonia.
Kang SW; Jo HG; Kim D; Jeong K; Lee J; Lee HJ; Yang S; Park S; Rhie SJ; Chung EK
J Crit Care; 2023 Dec; 78():154402. PubMed ID: 37634293
[TBL] [Abstract][Full Text] [Related]
11. Model-based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non-complicated methicillin-resistant staphylococcus aureus infection.
Zhang XS; Chen YL; Wang YZ; Chen C; Chen YJ; Xu FM; Dai Y; Shi DW; Lin GY; Yu XB; Xiang DZ; Zhang CH
Br J Clin Pharmacol; 2024 Feb; 90(2):452-462. PubMed ID: 37749762
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections.
Matsumoto K; Watanabe E; Kanazawa N; Fukamizu T; Shigemi A; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
Clin Pharmacol; 2016; 8():15-8. PubMed ID: 27099534
[TBL] [Abstract][Full Text] [Related]
13. Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation.
Yamada T; Nonaka T; Yano T; Kubota T; Egashira N; Kawashiri T; Oishi R
Int J Antimicrob Agents; 2012 Oct; 40(4):344-8. PubMed ID: 22818770
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of teicoplanin in children.
Ramos-Martín V; Paulus S; Siner S; Scott E; Padmore K; Newland P; Drew RJ; Felton TW; Docobo-Pérez F; Pizer B; Pea F; Peak M; Turner MA; Beresford MW; Hope WW
Antimicrob Agents Chemother; 2014 Nov; 58(11):6920-7. PubMed ID: 25224001
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection.
Ogawa R; Kobayashi S; Sasaki Y; Makimura M; Echizen H
Int J Clin Pharmacol Ther; 2013 May; 51(5):357-66. PubMed ID: 23458228
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic Model for Vancomycin Used in Open Heart Surgery: Model-Based Evaluation of Standard Dosing Regimens.
Alqahtani SA; Alsultan AS; Alqattan HM; Eldemerdash A; Albacker TB
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686154
[TBL] [Abstract][Full Text] [Related]
17. Optimal Teicoplanin Dosing Regimen in Neonates and Children Developed by Leveraging Real-World Clinical Information.
Yamada T; Emoto C; Fukuda T; Motomura Y; Inoue H; Ohga S; Ieiri I
Ther Drug Monit; 2022 Jun; 44(3):404-413. PubMed ID: 34629445
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics and pharmacodynamics of teicoplanin in neonates: making better use of C-reactive protein to deliver individualized therapy.
Ramos-Martín V; Neely MN; McGowan P; Siner S; Padmore K; Peak M; Beresford MW; Turner MA; Paulus S; Hope WW
J Antimicrob Chemother; 2016 Nov; 71(11):3168-3178. PubMed ID: 27543654
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.
Zhao W; Zhang D; Storme T; Baruchel A; Declèves X; Jacqz-Aigrain E
Br J Clin Pharmacol; 2015 Nov; 80(5):1197-207. PubMed ID: 26138279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
